Physician profile

Frederick M Chaleff

Cardiovascular Disease · Plantation, FL

NPI 1326011545

$11,911.77

in general payments reported to CMS, 2019-2025

33 companies · $1,897 in 2025

The $1,897 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,416.74

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $3,410.70 2019-2024 Amplatzer Amulet, Aveir, Dragonfly Opstar
Medtronic, INC. $2,839.29 2021-2025 Reveal Linq, Micra, Linq II
Janssen Pharmaceuticals, INC $656.56 2019-2024 Xarelto
Novartis Pharmaceuticals Corporation $655.33 2019-2025
Merck Sharp & Dohme LLC $498.77 2021-2025 Verquvo
E.R. Squibb & Sons, L.L.C. $486.91 2019-2025 Camzyos, Eliquis
Pfizer INC. $400.16 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $390.44 2021-2025 Jardiance
Boston Scientific Corporation $320.29 2022-2025 Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor
Amgen INC. $290.68 2019-2025 Repatha, Repatha
Kowa Pharmaceuticals America, INC. $278.05 2019-2023 Livalo
Amarin Pharma, INC. $225.26 2019-2022
Biosense Webster, INC. $192.26 2021-2022
Sanofi-Aventis U.S. LLC $183.26 2019-2024
Esperion Therapeutics, INC. $173.28 2021-2025 Nexletol
Show all 33 companies
CompanyGeneral paymentsYearsTop products
Philips North America LLC $134.98 2022-2024 (Cm9) Amb Mon & Diag Und
Astrazeneca Pharmaceuticals LP $133.48 2022-2025 Farxiga
Cardiofocus, INC. $122.50 2019
Novo Nordisk INC $99.55 2024-2025 Ozempic, Wegovy
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $89.51 2022-2023 Lifevest
Cvrx, INC. $49.80 2023 Barostim Neo System
Siemens Medical Solutions USA, INC. $44.96 2019
Astellas Pharma US INC $38.88 2020-2021
Agepha Pharma Fz LLC $24.72 2024 Lodoco
Lilly USA, LLC $23.33 2025 Zepbound
Chiesi USA, INC. $23.22 2019
Kiniksa Pharmaceuticals International, Plc $22.42 2024 Arcalyst
Impulse Dynamics (USA) INC. $22.19 2021
Heartflow, INC. $20.78 2025
Preventice Services, LLC $18.27 2021
Acist Medical Systems, INC. $14.80 2019
Medtronic Vascular, INC. $14.13 2020
Ge Healthcare $13.01 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Frederick M Chaleff

$11,911.77

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $1,897 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/14095/frederick-m-chaleff

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.